Social Europe

  • EU Forward Project
  • YouTube
  • Podcast
  • Books
  • Newsletter
  • Membership

What The EU Could Do To Eradicate Ebola

Thomas Pogge 6th January 2015

Thomas Pogge

Thomas Pogge

Imagine the first Ebola outbreak in 1976 had been in a rich part of the world. Somewhere near London, Brussels, Osaka, Sydney or Chicago. No doubt, pharmaceutical companies, building on early research into the disease, would have worked very hard to develop effective remedies and to do the required clinical trials to get them approved for marketing. Ebola would not have had a chance to stage a second major outbreak — let alone another dozen.

In fact, of course, the first outbreaks were in the Sudan and in Mobuto’s Congo (then Zaire), and subsequent ones occurred in other impoverished areas of Africa, not places where pharmaceuticals can be sold at patent-protected hundredfold mark-ups. And even with the latest, much larger outbreak — some 20,000 cases with 8,000 deaths — the urgently needed trials are conducted not by pharmaceutical companies but by the NGO Médecins Sans Frontières and by publicly funded agencies such as the U.S. Centers for Disease Control and Prevention.

Ebola’s flourishing is further favored by the fact that pharmaceutical companies have little interest in the two classes of medicines most likely to work against infectious diseases: vaccines and antimicrobials. Vaccines are unlucrative because they tend to be purchased in bulk by large buyers who can bargain down the price. Antimicrobials are unlucrative because they often either become ineffective as a resistant strain of the disease becomes prevalent or else are prescribed only rarely precisely to avoid such emergence of drug resistance.

It is easy to blame pharmaceutical companies for the problem. Their single-minded pursuit of profits leads them to pass up important challenges and to focus instead on medically unneeded me-too drugs, on the expensive development of lifestyle drugs (e.g., against hair loss and impotence), and on maintenance drugs for which they can extort well into the six digits per annum. But it would be fairer and more productive to blame ourselves first and foremost for regulating the pharmaceutical industry so as to give it all the wrong incentives. Companies go after profits; if we want them effectively to promote human health and justice in health care, then we must align their incentives with these goals.

How can we do this? In past work with Aidan Hollis, I have proposed creation of the Health Impact Fund (HIF). The HIF is a pay-for-performance scheme that would offer innovators the option to register any new medicine, thereby undertaking to make it available at or below manufacturing cost during its first 10 years on the market (roughly matching the effective patent life of conventionally rewarded medicines). The registrant would further commit to allowing, at no charge, generic production and distribution of the product after expiry of this reward period. In exchange, the registrant would participate during that decade in fixed annual reward pools divided among all registered products according to each drug’s measured health impact. The size of these pools could be chosen to incentivize an appropriate number of important R&D projects. At $6 billion annually, one-third of one percent of global military spending, the HIF might support some 25 new medicines at any time, with 2 or 3 entering and leaving each year.

The HIF would foster the development of new high-impact medicines and, in particular, turn the now-neglected diseases of the poor into some of the most lucrative pharmaceutical R&D opportunities. It would avoid the bias that currently favors maintenance drugs by fully rewarding health gains achieved by preventative and curative products. It would also discourage the development of me-too drugs by rewarding them only insofar as they produce health gains beyond those achieved by their similar predecessors.

The HIF would promote access to registered medicines by limiting their price to the lowest feasible cost of manufacture and distribution. Registrants would often benefit from selling to the very poor at extremely low prices—even below cost—because of the increased health impact they would thereby achieve.

The HIF would motivate registrants to care not about mere sales but about health gains. Registrants would focus their marketing on patients who can really benefit from their product, regardless of their socioeconomic status. Registrants would have a stake in ensuring that their medicines are widely available, competently prescribed, and optimally used.

Additional dramatic efficiency gains would arise from avoiding deadweight losses (no mark-ups) and counterfeiting: with the genuine item widely available at or below cost, making and selling fakes is unprofitable. The HIF would also avert much costly litigation: generic firms would lack incentives to compete, and registrants would lack incentives to suppress generic products. Registrants might therefore not even bother to file for patents in many countries.

Targeting infectious diseases in particular, the HIF could offer, specifically for registered antimicrobial drugs, an additional E-reward based on their preserved global efficacy. While health-impact or H-rewards are sensitive to the number of patients served and to the health gain a product achieves for each patient (relative to the treatment s/he would otherwise have received), E-rewards are sensitive to the percentage of patients susceptible to the medicine and to the health gain it brings to the average susceptible patient (relative to no treatment at all). Thus, an innovator could receive substantial E-rewards for a product that is used only rarely, in cases where other treatments fail. E-rewards pay for the protection we all enjoy by having an efficacious product in reserve.

Seeking to raise the sum of the two rewards, innovators would want to discourage low-value uses of their product (where the expected loss in E exceeds the expected gain in H plus any permissible price mark-up). E-rewards might last an additional 5—10 years beyond the 10-year period of H-rewards so as to give the innovator an incentive to continue its efforts to provide the medicine at a low price and to preserve its efficacy.

The reward scheme might be complemented by a new intergovernmental agency for infectious diseases, organized perhaps as a corporation on the model of the Global Fund. Harvey Rubin and his collaborators at the University of Pennsylvania have recently proposed such an agency under the name of Global Governance Structure for Infectious Disease (GGSID). This agency could oversee and coordinate worldwide efforts in basic research, vaccinations, surveillance, diagnostics, infection control, general antibiotic stewardship and other public health measures focused on infectious diseases. It would control the use and licensing of all antimicrobials and administer the E-reward scheme and the supplementary efforts. It could be financed through user fees on all non-human uses of antimicrobials worldwide and on all human uses of any (including generic) antimicrobials in high-income countries. With human antimicrobial expenditures at over $30 billion, $3 billion could easy be raised just from the latter funding source.

At relatively low cost of $9 billion each year, such an expanded Health Impact Fund would greatly strengthen our arsenal of vaccines and antimicrobials, thereby ensuring a rapid and effective response to new infectious diseases (which emerge at a rate of about four per annum) and to new, drug-resistant strains of old ones. Millions of lives would be saved, especially among the world’s poor. And all human beings would be much better protected against the ever-changing threats from infectious diseases.

Confronting ever-rising health care costs by tying reward to performance, the HIF would pay for itself many times over: through lower prices for advanced medicines and by averting disease with its associated costs of medical treatment and lost productivity. It would save millions of people each year from death or serious illness. It would be an exemplary global public good to which all nations could contribute and from which all would benefit.

We had promising Ebola medicines decades ago and we let them sit on the shelf, undeveloped. Let us not do the same with the HIF idea. With a few leading developing countries, including India and Brazil, let Europe take the lead in piloting the HIF reward mechanism and then promote its implementation through the G20.

Thomas Pogge

Thomas Pogge is Leitner Professor of Philosophy and International Affairs at Yale University and Professor of Political Philosophy at the University of Central Lancashire.

Harvard University Press Advertisement

Social Europe Ad - Promoting European social policies

We need your help.

Support Social Europe for less than €5 per month and help keep our content freely accessible to everyone. Your support empowers independent publishing and drives the conversations that matter. Thank you very much!

Social Europe Membership

Click here to become a member

Most Recent Articles

09d21a9 The Future of Social Democracy: How the German SPD can Win AgainHenning Meyer
u42198346 How Trump’s Tariff Regime Fuels Global OligarchyGabriel Zucman
u421983462 041df6feef0a 3 Universities Under Siege: A Global Reckoning for Higher EducationManuel Muñiz
u4219836ab582 af42 4743 a271 a4f423d1926d 0 How Trade Unions Can Champion Solidarity in Europe’s Migration DebateNeva Löw
u421983467298feb62884 0 The Weak Strongman: How Trump’s Presidency Emboldens America’s EnemiesTimothy Snyder

Most Popular Articles

u4219834647f 0894ae7ca865 3 Europe’s Businesses Face a Quiet Takeover as US Investors CapitaliseTej Gonza and Timothée Duverger
u4219834674930082ba55 0 Portugal’s Political Earthquake: Centrist Grip Crumbles, Right AscendsEmanuel Ferreira
u421983467e58be8 81f2 4326 80f2 d452cfe9031e 1 “The Universities Are the Enemy”: Why Europe Must Act NowBartosz Rydliński
u42198346761805ea24 2 Trump’s ‘Golden Era’ Fades as European Allies Face Harsh New RealityFerenc Németh and Peter Kreko
startupsgovernment e1744799195663 Governments Are Not StartupsMariana Mazzucato
u421986cbef 2549 4e0c b6c4 b5bb01362b52 0 American SuicideJoschka Fischer
u42198346769d6584 1580 41fe 8c7d 3b9398aa5ec5 1 Why Trump Keeps Winning: The Truth No One AdmitsBo Rothstein
u421983467 a350a084 b098 4970 9834 739dc11b73a5 1 America Is About to Become the Next BrexitJ Bradford DeLong
u4219834676ba1b3a2 b4e1 4c79 960b 6770c60533fa 1 The End of the ‘West’ and Europe’s FutureGuillaume Duval
u421983462e c2ec 4dd2 90a4 b9cfb6856465 1 The Transatlantic Alliance Is Dying—What Comes Next for Europe?Frank Hoffer

S&D Group in the European Parliament advertisement

Cohesion Policy

S&D Position Paper on Cohesion Policy post-2027: a resilient future for European territorial equity”,

Cohesion Policy aims to promote harmonious development and reduce economic, social and territorial disparities between the regions of the Union, and the backwardness of the least favoured regions with a particular focus on rural areas, areas affected by industrial transition and regions suffering from severe and permanent natural or demographic handicaps, such as outermost regions, regions with very low population density, islands, cross-border and mountain regions.

READ THE FULL POSITION PAPER HERE

ETUI advertisement

HESA Magazine Cover

What kind of impact is artificial intelligence (AI) having, or likely to have, on the way we work and the conditions we work under? Discover the latest issue of HesaMag, the ETUI’s health and safety magazine, which considers this question from many angles.

DOWNLOAD HERE

Eurofound advertisement

Ageing workforce
How are minimum wage levels changing in Europe?

In a new Eurofound Talks podcast episode, host Mary McCaughey speaks with Eurofound expert Carlos Vacas Soriano about recent changes to minimum wages in Europe and their implications.

Listeners can delve into the intricacies of Europe's minimum wage dynamics and the driving factors behind these shifts. The conversation also highlights the broader effects of minimum wage changes on income inequality and gender equality.

Listen to the episode for free. Also make sure to subscribe to Eurofound Talks so you don’t miss an episode!

LISTEN NOW

Foundation for European Progressive Studies Advertisement

Spring Issues

The Spring issue of The Progressive Post is out!


Since President Trump’s inauguration, the US – hitherto the cornerstone of Western security – is destabilising the world order it helped to build. The US security umbrella is apparently closing on Europe, Ukraine finds itself less and less protected, and the traditional defender of free trade is now shutting the door to foreign goods, sending stock markets on a rollercoaster. How will the European Union respond to this dramatic landscape change? .


Among this issue’s highlights, we discuss European defence strategies, assess how the US president's recent announcements will impact international trade and explore the risks  and opportunities that algorithms pose for workers.


READ THE MAGAZINE

Hans Böckler Stiftung Advertisement

WSI Report

WSI Minimum Wage Report 2025

The trend towards significant nominal minimum wage increases is continuing this year. In view of falling inflation rates, this translates into a sizeable increase in purchasing power for minimum wage earners in most European countries. The background to this is the implementation of the European Minimum Wage Directive, which has led to a reorientation of minimum wage policy in many countries and is thus boosting the dynamics of minimum wages. Most EU countries are now following the reference values for adequate minimum wages enshrined in the directive, which are 60% of the median wage or 50 % of the average wage. However, for Germany, a structural increase is still necessary to make progress towards an adequate minimum wage.

DOWNLOAD HERE

Social Europe

Our Mission

Team

Article Submission

Advertisements

Membership

Social Europe Archives

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Miscellaneous

RSS Feed

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641